TTY Biopharm Company Limited
http://eng.tty.com.tw/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From TTY Biopharm Company Limited
Asia Deal Watch: Hansoh, TiumBio Join Forces On Endometriosis Drug In Greater China
Plus deals involving Shionogi/ Grünenthal, CR Biopharma/ImmVira, Elevation Oncology/CSPC, Everest Medicines/TTY Biopharm and Dr. Reddy’s/Slayback
Trial Hot Spot: Australia's Attractions To The Korean Industry
Ausbiotech's CEO and the Australian government’s Senior Trade and Investment Commissioner in South Korea talk to Scrip on the sidelines of the Bio Korea 2022 meeting about what makes Australia an attractive clinical trial destination for Korean and other foreign pharma firms, as well as about collaborations and other opportunities between the two countries.
A Closer Look At The Korean Microbiome Therapeutic Landscape
Scrip takes an infographic look at various factors to keep an eye on in South Korea's rapidly developing microbiome therapy landscape this year, including emerging companies and their pipelines.
Korea Policies To Shift To Non-COVID Areas In 2022?
The Pink Sheet takes a look back at major policy developments in South Korea in 2021 and ahead at what’s in store for the coming year.
Company Information
- Industry
- Biotechnology
- Contract Research Organization-CRO
- Pharmaceuticals
- Contract Manufacturing Organization
-
Pharmaceuticals
- Generic Drugs
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice